Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used to treat macular telangiectasia type 2. It is administered into the recipient's eye during a single surgical procedure. It works by expressing recombinant human ciliary neurotrophic factor, a factor that may promote the survival and maintenance of the macular photoreceptors. It was approved for medical use in the United States in March 2025.
Facts
Classification
Approval Status First Approved / Isolated Year Sources
1. Revakinagene taroretcel (Wikipedia)
Lead sectionQuote, Lead section
Revakinagene taroretcel was approved for medical use in the United States in March 2025.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.